Introduction
============

Kidney cancer is one of the top 10 types of cancer in terms of incidence and mortality rate in men and women, worldwide. Renal cell carcinoma (RCC) accounts for \~90% of all kidney cancer cases ([@b1-ol-0-0-10960],[@b2-ol-0-0-10960]). RCC mainly includes the papillary subtype, the chromophobe subtype and clear cell RCC (ccRCC) ([@b3-ol-0-0-10960]); ccRCC is the most common subtype. Furthermore, 30% of patients with kidney cancer present with metastatic disease ([@b4-ol-0-0-10960]). Surgical resection remains the most effective therapeutic strategy against clinically localized ccRCC. In addition, current treatments are focused on vascular endothelial growth factor receptor (VEGFR)-targeted therapy and mammalian target of rapamycin (mTOR) inhibition ([@b5-ol-0-0-10960],[@b6-ol-0-0-10960]). However, 30% patients with ccRCC are already at an advanced stage at the time of diagnosis ([@b7-ol-0-0-10960]), and the current therapeutic strategies offer limited efficacy. The development of novel therapeutic drugs for ccRCC is therefore challenging and it is crucial to determine efficient prognostic biomarkers of ccRCC in order to develop an effective treatment.

As the best-known inhibitory neurotransmitter in the brain, γ-aminobutyric acid (GABA) activates three pharmacologically and structurally distinct classes of receptor: GABA~A~, GABA~B~ and GABA~C~ ([@b8-ol-0-0-10960]). Among them, GABA~A~ is the major inhibitory receptor in the central nervous system ([@b9-ol-0-0-10960],[@b10-ol-0-0-10960]). Notably, GABA~A~ receptor subunit θ (GABRQ) can bind with other receptors to form a functional chloride channel that mediates inhibitory synaptic transmission in the mature central nervous system ([@b9-ol-0-0-10960]). GABA and receptor GABA~A~ are also present in peripheral tissues, including cancerous cells, but their precise function is poorly understood ([@b10-ol-0-0-10960]). A previous study revealed that GABRQ is overexpressed in hepatocellular carcinoma and that GABA promotes the proliferation of cancer cells through GABRQ ([@b11-ol-0-0-10960]). However, the prognostic significance of GABRQ in ccRCC remains unknown. To the best of our knowledge, the present study was the first to report on the mRNA expression levels of *GABRQ* in samples obtained from the International Cancer Genome Consortium (ICGC) ([@b12-ol-0-0-10960]) and The Cancer Genome Atlas (TCGA) ([@b13-ol-0-0-10960],[@b14-ol-0-0-10960]) primary-ccRCC cohorts. The results suggested that the mRNA expression levels of *GABRQ* may be considered an effective prognostic marker of ccRCC.

Materials and methods
=====================

### Patient data and characteristics

The clinical and transcriptomic data from patients with ccRCC were downloaded from TCGA ([@b13-ol-0-0-10960],[@b14-ol-0-0-10960]) and ICGC ([@b12-ol-0-0-10960]) databases in March 2018. To identify the prognostic significance of *GABRQ* ([Table I](#tI-ol-0-0-10960){ref-type="table"}). TCGA and ICGC databases are approved for the quality of patient data and are widely used in numerous studies. No additional quality assessment was performed, since data that were not produced by a reputable institution were excluded. Samples with insufficient survival information were excluded ([@b15-ol-0-0-10960],[@b16-ol-0-0-10960]). The overall study workflow is presented in [Fig. 1](#f1-ol-0-0-10960){ref-type="fig"}. Comparative analyses between normal and tumor cells was conducted with the use of publicly available microarray data from the Oncomine database. To relate *GABRQ* copy number ([@b17-ol-0-0-10960]), the GSE20306 dataset (n=449) was used.

### Statistical analyses

Wilcoxon\'s rank-sum test was performed to identify the differences in *GABRQ* expression between early and late stages of ccRCC in TCGA and ICGC cohorts. Survival analyses to predict overall survival of patients with ccRCC and the associated statistical analyses were conducted using R software (version 3.5.0; The R Foundation for Statistical Computing; 2018; <http://www.R-project.org>). Furthermore, to validate the prognostic value of *GABRQ*, the following statistical methods were carried out: i) Uno\'s C-index; ii) area under the curve (AUC) in receiver operating characteristics (ROC) at 5 years; and iii) P-value from log-rank test of Kaplan-Meier survival curve to evaluate the accuracy of the discrimination, as described previously using the 'survival' and 'survAUC' R packages ([@b16-ol-0-0-10960],[@b18-ol-0-0-10960]). The C-index is a well-known parameter of the fit of a survival model within a continuous time period during a clinical study ([@b19-ol-0-0-10960],[@b20-ol-0-0-10960]). Regarding the survival curve analyses, the optimal cutoff value that had the maximal Uno\'s C-index by 5-fold cross-validation was determined as previously described ([@b15-ol-0-0-10960],[@b16-ol-0-0-10960],[@b18-ol-0-0-10960]). Since the RNA sequencing data from TCGA and ICGC had been obtained using different sequencing and normalization methods, the absolute value of gene expression varied widely among datasets. For these reasons, the optimal cutoff values were different for each cohort. T and M stage information in both cohorts was sufficient to perform subgroup analysis; however, as there was no information for N stage, subgroup analysis was not performed ([@b12-ol-0-0-10960]--[@b14-ol-0-0-10960]). Univariate and multivariate Cox regression analyses were performed to compare the effects of *GABRQ* expression (as a categorical value) on prognosis and other clinical variables.

Results
=======

### Patient characteristics

A total of 446 and 91 patients from the TCGA and ICGC databases, respectively, were analyzed in the present study ([@b12-ol-0-0-10960]--[@b14-ol-0-0-10960],[@b21-ol-0-0-10960],[@b22-ol-0-0-10960]). The 446 patients from TCGA comprised 290 men and 156 women. The 91 patients from the ICGC comprised 52 men and 39 women. The patient characteristics investigated in the present study are listed in [Table I](#tI-ol-0-0-10960){ref-type="table"}.

### Downregulation of GABRQ at late stages of ccRCC

The mRNA expression levels of *GABRQ* were compared among samples from early (TI and II), late (TIII and IV), nonmetastatic (M0) and metastatic (M1, primary tumor) stages of ccRCC ([Table II](#tII-ol-0-0-10960){ref-type="table"}) from TCGA and ICGC cohorts. The mRNA expression levels of *GABRQ* were much higher in early (TI and II) and nonmetastatic (M0) ccRCC samples compared with in late (TIII and IV) and metastatic (M1, primary tumor) ccRCC samples in TCGA ([Fig. 2](#f2-ol-0-0-10960){ref-type="fig"}). The similar trend was seen in the ICGC but this was not statistically significant. In addition, *GABRQ* copy numbers are decreased in several types of cancers, including kidney cancers, leukemia, multiple myeloma and prostate cancers ([Fig. 3](#f3-ol-0-0-10960){ref-type="fig"}).

### Prognostic value of GABRQ mRNA expression in patients with ccRCC

To identify the prognostic significance of *GABRQ* in ccRCC, survival curves for *GABRQ* mRNA expression ([Table II](#tII-ol-0-0-10960){ref-type="table"}) and survival within TCGA ([Fig. 4](#f4-ol-0-0-10960){ref-type="fig"}) and ICGC ([Fig. 5](#f5-ol-0-0-10960){ref-type="fig"}) cohorts were analyzed. Patients with low *GABRQ* mRNA expression in the primary tumor in the two cohorts had significantly shorter overall survival time compared with patients with higher *GABRQ* mRNA expression ([Figs. 4](#f4-ol-0-0-10960){ref-type="fig"} and [5](#f5-ol-0-0-10960){ref-type="fig"}). Prognostic value was then examined using multivariate Cox regression analysis ([Table III](#tIII-ol-0-0-10960){ref-type="table"}). The multivariate analysis conformed that GABRQ mRNA expression was an independent prognostic factor for ccRCC.

### C-index and AUC of GABRQ

To assess whether *GABRQ* mRNA expression could be considered a prognostic biomarker of ccRCC, Uno\'s C-index based on the time-dependent AUC analysis and the AUC of the receiver operating characteristic curve at 5 years were examined. The results demonstrated that *GABRQ* mRNA had high C-index values in the two independent cohorts (TCGA: 0.644 and ICGC: 0.670; [Fig. 6A](#f6-ol-0-0-10960){ref-type="fig"} and [Table IV](#tIV-ol-0-0-10960){ref-type="table"}). The 5-year ROC curves yielded high AUC values for both TCGA and ICGC (0.611 and 0.650, respectively; [Fig. 6B](#f6-ol-0-0-10960){ref-type="fig"}). These results suggest that GABRQ mRNA expression is useful to predict prognosis of patients with ccRCC.

Discussion
==========

Classification of ccRCC includes localized and advanced ccRCC. Numerous therapeutic options are currently available for localized ccRCC; however the most effective therapy remains surgical resection. Furthermore, there are no suitable drugs for the adjuvant treatment of local kidney cancer ([@b23-ol-0-0-10960]). Current treatments of advanced ccRCC target VEGFR and mTOR ([@b24-ol-0-0-10960]). Due to recent advances in biotechnology, including next-generation sequencing, bioinformatics has rapidly developed and highlighted a great number of potential biomarkers ([@b25-ol-0-0-10960]). Numerous patient databases are freely available to the public, including the Gene Expression Omnibus and TCGA, which contain extensive gene expression data that can be used to determine novel biomarkers ([@b26-ol-0-0-10960]). Notably, these databases can be used to identify essential biomarkers for effective prognosis of ccRCC. In addition, molecular markers that can be used in combination with the current cancer staging systems need to be identified.

The present study demonstrated that *GABRQ* mRNA expression could be a prognostic marker of ccRCC. In particular, low *GABRQ* mRNA expression was associated with a poor prognosis among patients with ccRCC. A previous study indicated that *GABRQ* is overexpressed in hepatocellular carcinoma and that GABA promotes the proliferation of cancer cells through GABRQ ([@b11-ol-0-0-10960]). In addition, GABA can inhibit colon cancer cell migration associated with the norepinephrine-induced pathway ([@b27-ol-0-0-10960]), and via the GABA~B~ pathway, which is involved in prostate cancer metastasis and invasion ([@b28-ol-0-0-10960]). Although GABRQ may contribute to cancer progression, it has been reported that it can serve additional roles in other types of disease, including essential tremor ([@b8-ol-0-0-10960]) and migraines ([@b29-ol-0-0-10960]).

This study presented some methodological limitations. Since the expression data of *GABRQ* in the two independent cohorts were obtained through different methods, the absolute expression values differed for each cohort. The cutoff values of *GABRQ* were therefore different for each cohort. Most cohort studies present the same technical limitations, unless data processing was performed by the same hospital and at the same time. To identify the involvement of *GABRQ* in ccRCC, experiments need to be conducted at the protein level. However, there are numerous studies that have determined prognostic biomarkers based on mRNA expression (for example oncotype DX ([@b30-ol-0-0-10960]), MammaPrint ([@b31-ol-0-0-10960]) and gene signatures tests ([@b19-ol-0-0-10960],[@b32-ol-0-0-10960]--[@b34-ol-0-0-10960])). Although the present study did not confirm GABRQ function at the protein level, mRNA-based studies are emerging in this field, and represent time- and cost-effective methods.

The main conclusions from the present study may strengthen the foundation of precision medicine via analysis of transcriptomic data. mRNA-based prognostic markers have been identified in numerous diseases, including cancer, and certain markers are so accurate that they can be included in clinical guidelines ([@b19-ol-0-0-10960],[@b32-ol-0-0-10960],[@b35-ol-0-0-10960]--[@b37-ol-0-0-10960]). The results from both cohorts analyzed in this study demonstrated that lower *GABRQ* mRNA expression was associated with a worse ccRCC prognosis. In addition, *GABRQ* copy numbers were much lower in numerous types of cancer, including kidney cancer, leukemia, multiple myeloma and prostate cancer, according to genomic analyses from Oncomine ([@b17-ol-0-0-10960]) ([Fig. 6](#f6-ol-0-0-10960){ref-type="fig"}). Although there are limitations to transcriptome-based studies of *GABRQ*, the results from the present study suggested that *GABRQ* mRNA expression may be considered a novel prognostic biomarker of ccRCC.
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![Flowchart of the present study. AUC, area under the curve; ICGA, International Cancer Genome Consortium; TCGA, The Cancer Genome Atlas.](ol-18-06-5731-g00){#f1-ol-0-0-10960}

![Comparison of *GABRQ* mRNA expression among early (TI and II), late (TIII and IV), nonmetastatic (M0), and metastatic (M1, primary tumor) stages of ccRCC samples from TCGA and ICGC cohorts. (A-C) *GABRQ* expression values in ccRCC samples from TCGA cohort. (D-F) *GABRQ* expression values in ccRCC samples from ICGC cohort. ccRCC, clear cell renal cell carcinoma; *GABRQ*, γ-aminobutyric acid receptor A subunit θ; ICGA, International Cancer Genome Consortium; TCGA, The Cancer Genome Atlas.](ol-18-06-5731-g01){#f2-ol-0-0-10960}

![*GABRQ* gene expression in tumors. The copy number of *GABRQ* in tumors in the Oncomine database corresponds to the GSE20306 dataset (n=449) ([@b36-ol-0-0-10960]). The x-axis represents the number of patients with different types of cancer: 0, Normal (n=4); 1, Bladder (n=9); 2, Brain and central nervous system (n=17); 3, Breast (n=21); 4, Cervical (n=7); 5, Colorectal (n=21); 6, Esophageal (n=4); 7, Gastric (n=5); 8, Head and neck (n=6); 9, Kidney (n=8); 10, Leukemia (n=33); 11, Liver (n=9); 12, Lung (n=78); 13, Lymphoma (n=41); 14, Melanoma (n=12); 15, Myeloma (n=5); 16, Other (n=7); 18, Pancreatic (n=9); 19, Prostate (n=5) and 20, Sarcoma (n=20). *GABRQ*, γ-aminobutyric acid receptor A subunit θ.](ol-18-06-5731-g02){#f3-ol-0-0-10960}

![Kaplan-Meier estimation of *GABRQ* mRNA expression as a prognostic biomarker in patients with ccRCC. The association of *GABRQ* gene expression with overall survival among patients from TCGA was examined. Gene expression was analyzed for (A) all patients, (B) stage I and II, (C) stage III and IV, (D) T stage I and II, (E) T stage III and IV, (F) M stage 0, and (G) M stage 1. P-values were calculated by the log-rank test and are provided in the bottom left of each plot. ccRCC, clear cell renal cell carcinoma; *GABRQ*, γ-aminobutyric acid receptor A subunit θ; TCGA, The Cancer Genome Atlas; M0, non-metastatic; M1, primary tumor.](ol-18-06-5731-g03){#f4-ol-0-0-10960}

![Kaplan-Meier estimation of *GABRQ* mRNA expression as a prognostic biomarker in patients with ccRCC. The association of *GABRQ* gene expression with overall survival among patients from the ICGC was examined. Gene expression was analyzed for (A) all patients, (B) stage I and II, (C) stage III and IV, (D) T stage I and II, (E) T stage III and IV, (F) M stage 0, and (G) M stage 1. P-values were calculated by the log-rank test and are provided in the bottom left of each plot. ccRCC, clear cell renal cell carcinoma; *GABRQ*, γ-aminobutyric acid receptor A subunit θ; ICGC, International Cancer Genome Consortium; M0, non-metastatic; M1, primary tumor.](ol-18-06-5731-g04){#f5-ol-0-0-10960}

![Time-dependent AUC and ROC curve analysis at 5 years according to *GABRQ* mRNA expression in TCGA and ICGC samples. Analysis of *GABRQ* gene expression in TCGA (red) and ICGC (blue) samples according to (A) time-dependent AUC and (B) ROC curve at 5 years. C-index values are provided in the bottom right corner of each plot. AUC, area under the curve; *GABRQ*, γ-aminobutyric acid receptor A subunit θ; ICGA, International Cancer Genome Consortium; ROC, receiver operating characteristic; TCGA, The Cancer Genome Atlas.](ol-18-06-5731-g05){#f6-ol-0-0-10960}

###### 

Characteristics of patients from TCGA and ICGC databases.

  Characteristic                    TCGA (%)      ICGC (%)
  --------------------------------- ------------- -------------
  ATCC stage                                      
    I                               216 (48.4)    48 (52.7)
    II                              46 (10.3)     12 (13.2)
    III                             111 (24.9)    13 (14.3)
    IV                              71 (15.9)     9 (9.9)
    Not available                   2 (0.4)       9 (9.9)
  Grade                                           
    I                               9 (2.0)       --
    II                              189 (42.4)    --
    III                             175 (39.2)    --
    IV                              68 (15.2)     --
    Not available                   5 (1.1)       --
  Sex                                             
    Male                            290 (65.0)    52 (57.1)
    Female                          156 (35.0)    39 (42.9)
  Age (mean ± standard deviation)   60.62±12.80   60.47±10.03
  Total number of patients          446           91

AJCC, American Joint Committee on Cancer; ICGA, International Cancer Genome Consortium; TCGA, The Cancer Genome Atlas.

###### 

Optimal cutoff values for γ-aminobutyric acid receptor A subunit θ expression in TCGA and ICGC cohorts.

  Dataset   Cutoff value
  --------- --------------
  TCGA      4.9689
  ICGC      0.1440

ICGA, International Cancer Genome Consortium; TCGA, The Cancer Genome Atlas.

###### 

Univariate and multivariate analyses of overall survival in each cohort.

  A, TCGA                                                                                                                                                                                                                                                          
  --------------------------- -------------------------------------------------------- --------------------------------- ----------------------------- ------------- ------------------------------------------------------- ----------------------------- ------- --------
  *GABRQ* (categorical)       \<0.001^[c](#tfn5-ol-0-0-10960){ref-type="table-fn"}^    0.483                             0.348                         0.672         \<0.001^[c](#tfn5-ol-0-0-10960){ref-type="table-fn"}^   0.562                         0.401   0.788
  Age                         \<0.001 ^[c](#tfn5-ol-0-0-10960){ref-type="table-fn"}^   1.033                             1.018                         1.047         \<0.001^[c](#tfn5-ol-0-0-10960){ref-type="table-fn"}^   1.030                         1.015   1.046
  Stage (I, II vs. III, IV)   \<0.001^[c](#tfn5-ol-0-0-10960){ref-type="table-fn"}^    3.478                             2.474                         4.888         \<0.001^[c](#tfn5-ol-0-0-10960){ref-type="table-fn"}^   2.883                         2.012   4.132
  Sex (female vs. male)       0.333                                                    0.850                             0.612                         1.181         0.859                                                   0.969                         0.688   1.366
  Grade (I, II vs. III, IV)   \<0.001^[c](#tfn5-ol-0-0-10960){ref-type="table-fn"}^    2.247                             1.572                         3.212         0.135                                                   1.340                         0.913   1.968
                                                                                                                                                                                                                                                                   
  **B, ICGC**                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                   
                              **Univariate Cox regression**                            **Multivariate Cox regression**                                                                                                                                             
                                                                                                                                                                                                                                                                   
  **Variable**                **P-value**                                              **Hazard ratio**                  **95% confidence interval**   **P-value**   **Hazard ratio**                                        **95% confidence interval**           
                                                                                                                                                                                                                                                                   
  *GABRQ* (categorical)       0.002^[b](#tfn4-ol-0-0-10960){ref-type="table-fn"}^      0.283                             0.126                         0.638         0.014^[a](#tfn3-ol-0-0-10960){ref-type="table-fn"}^     0.343                         0.146   0.804
  Age                         0.109                                                    1.031                             0.993                         1.071         0.448                                                   1.015                         0.976   1.056
  Stage                       \<0.001^[c](#tfn5-ol-0-0-10960){ref-type="table-fn"}^    4.796                             2.264                         10.16         \<0.001^[c](#tfn5-ol-0-0-10960){ref-type="table-fn"}^   4.628                         2.094   10.232
  (I, II vs. III, IV)                                                                                                                                                                                                                                              
  Sex (female vs. male)       0.863                                                    1.066                             0.517                         2.194         0.307                                                   0.657                         0.294   1.470

P\<0.05

P\<0.01

P\<0.001. *GABRQ*, γ-aminobutyric acid receptor A subunit θ; ICGA, International Cancer Genome Consortium; TCGA, The Cancer Genome Atlas.

###### 

C-index values of *GABRQ* in the specified categories of TCGA and ICGC cohorts.

                   C-index   
  ---------------- --------- -------
  All patients     0.644     0.670
  Stage I & II     0.597     0.639
  Stage III & IV   0.634     0.585
  T (I & II)       0.600     0.621
  T (III & IV)     0.645     0.671
  M0               0.623     0.652
  M1               0.644     0.655

ICGA, International Cancer Genome Consortium; TCGA, The Cancer Genome Atlas.
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